Grade 3b Follicular Lymphoma Clinical Trial
Official title:
An Italian Experience on Grade 3b Follicular Lymphoma
Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab
containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma.
Also an histological central review is planned in order to re-assess baseline diagnosis
according to new 2016 World Health Organization (WHO) criteria.
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05890352 -
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
|
Phase 2 | |
| Recruiting |
NCT06026319 -
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
|
Phase 1 | |
| Completed |
NCT02541565 -
Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04799275 -
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
|
Phase 2/Phase 3 | |
| Terminated |
NCT04156828 -
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05583149 -
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
|
Phase 2 | |
| Recruiting |
NCT05633615 -
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03150329 -
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
|
Phase 1 | |
| Recruiting |
NCT05455697 -
Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Approved for marketing |
NCT05733650 -
Expanded Access Program for Epcoritamab
|